Tr1x is a biotechnology company developing novel cellular immunotherapies for patients with autoimmune and inflammatory diseases.
Tr1x has raised $50.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in October 2025.
Tr1x's investors include The Column Group, Neva SGR, Alexandria Venture Investments, California Institute for Regenerative Medicine.
Tr1x is headquartered in San Diego, United States.
Tr1x is a biotechnology company developing novel cellular immunotherapies for patients with autoimmune and inflammatory diseases.
Tr1x is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Tr1x — Funding & Investors." VCBacked, October 14, 2025, https://www.vcbacked.co/company/tr1x. Accessed August 15, 2026.
VCBacked. (2025). Tr1x — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/tr1x
{{cite web |title=Tr1x — Funding & Investors |url=https://www.vcbacked.co/company/tr1x |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated